ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Metropolis delivered a robust 16% revenue growth, beating prior 12-13% organic guidance. Operating leverage is kicking in, with H1 margins expanding 190 bps despite heavy monsoon headwinds and no price hikes.
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 26-27. The record date is 9 November 2026.
Metropolis Healthcare posted Q2 FY27 revenue up 16% to ₹497 crore and PAT up 43% to ₹75 crore. Board declared a ₹1 per share interim dividend.
Q2 FY27 revenue INR 497 Cr (+16% YoY), EBITDA INR 135 Cr at 27.2% margin, PAT INR 75 Cr (+43%). H1 revenue INR 947 Cr (+16%). Strategy is Metropolis 3.0, focused on tech, science and profitable growth.
Metropolis Healthcare Ltd reported revenue from operations of ₹496.8 Cr (+15.8% YoY) and net profit of ₹75.5 Cr (+42.7% YoY) for Q2 FY27.
Metropolis Healthcare granted 24,060 RSUs and 3,58,920 ESOPs under its 2025 plans, and allotted 65,600 shares under its RSU Plan 2020.
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Metropolis Healthcare Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides details on the company's equity share distribution.
Metropolis Healthcare allotted 9,516 equity shares under its RSU Plan, 2020. This issuance follows the exercise of vested stock units by employees.